Biosimilar Switching: What Happens When You Change from Originator

When you’ve been taking a biologic medication for years - maybe for rheumatoid arthritis, psoriasis, or Crohn’s disease - switching to a biosimilar isn’t just a change in pill color or packaging. It’s a shift in how your body responds, how your doctor monitors you, and even how you feel emotionally. Many patients are told the switch is safe. But what does that really mean? And what actually happens when you go from the original drug to a biosimilar?

What Is a Biosimilar, Anyway?

A biosimilar isn’t a generic. That’s the first thing to understand. Generics are exact chemical copies of small-molecule drugs like aspirin or statins. Biosimilars, on the other hand, are made from living cells - proteins, antibodies, enzymes - and even though they’re designed to be nearly identical to the original biologic, they’re not carbon copies. Think of it like two handmade wooden chairs: they look the same, have the same function, and were built from the same blueprint, but slight differences in grain, finish, or nail placement exist. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) require biosimilars to show no clinically meaningful difference in safety, purity, or potency compared to the originator. That means your immune system shouldn’t react differently. Your disease shouldn’t flare. Your bloodwork shouldn’t change.

The first biosimilar approved in the U.S. was Zarxio (filgrastim-sndz) in 2015. Since then, 37 biosimilars have been approved, mostly targeting inflammation-causing proteins like TNF-alpha. Drugs like infliximab and adalimumab - the ones used for arthritis and IBD - make up about 70% of all biosimilar use. And they’re cheaper. Often 15% to 35% less than the originator. That’s why insurers and governments are pushing for switches.

What Happens When You Switch?

Studies have followed tens of thousands of patients who switched from originator biologics to biosimilars. The largest, the NOR-Switch trial, tracked 481 people with inflammatory diseases who switched from originator infliximab to its biosimilar, CT-P13. At one year, 52.6% of the biosimilar group were still on treatment. The originator group? 60%. That difference wasn’t statistically significant. In plain terms: people stopped taking either drug at roughly the same rate - not because the biosimilar failed, but because of side effects, lifestyle changes, or personal choice.

Another study looked at patients switching from one biosimilar to another - say, from CT-P13 to SB2. Researchers measured drug levels in the blood, antibody responses, and disease activity. They found no meaningful changes. Trough levels stayed steady. Anti-drug antibodies stayed low. Disease scores didn’t spike. In fact, over 140 patients across multiple switches showed only 3 cases of immunogenicity per 100 patient-years - that’s less than 1%.

For inflammatory bowel disease (IBD), a 2021 study showed 90.6% of patients maintained remission after switching from one biosimilar to another. Fecal calprotectin - a key marker of gut inflammation - stayed almost unchanged. In psoriasis, Danish data showed 79% of patients stayed on biosimilar adalimumab after switching, compared to 81% before. The difference? Not enough to call it a failure.

Why Do Some People Stop Taking It?

Here’s the uncomfortable truth: many people stop taking biosimilars not because they don’t work - but because they think they don’t.

There’s a well-documented phenomenon called the nocebo effect. If you’re told switching might cause problems, you’re more likely to notice a headache, fatigue, or a mild flare - even if your blood tests are normal. One study found 32.7% of patients reported new symptoms after switching, even though their disease activity hadn’t changed. Reddit threads are full of posts like: “I felt worse after the switch,” or “My doctor says it’s the same, but I know my body.”

Real side effects do happen - but they’re rare. Injection site reactions? About 7.8% in adalimumab biosimilar users. A slight increase in skin rashes? Seen in some psoriasis studies. But these aren’t signs the drug is unsafe. They’re just different ways the body reacts to minor formulation differences - like a change in preservatives or stabilizers.

The biggest reason for discontinuation? Not clinical failure. It’s fear. Lack of trust. Poor communication.

Who Shouldn’t Switch?

Switching works best when your disease is stable. If your DAS28 score (a measure of arthritis activity) is below 3.2, or your Crohn’s disease is in remission with normal calprotectin levels - you’re a good candidate.

But if you’re actively flaring, recently changed doses, or have had multiple drug failures, switching might not be the right move. The same goes for patients who’ve had serious allergic reactions or developed high levels of anti-drug antibodies. In those cases, doctors usually recommend staying on the original drug.

And what about switching between biosimilars? The data is mixed. Some studies show 90% retention. Others show 15% of IBD patients stopped after switching from one biosimilar to another. Why? It’s unclear. Maybe it’s the number of switches. Maybe it’s psychological. But experts agree: multiple switches aren’t yet proven to be risky - but they’re not routine either.

How Is the Switch Managed?

A good switch isn’t a surprise. It’s a process.

• Pre-switch counseling: At least 20 minutes with your doctor. No jargon. Just clear talk: “This is the same drug, just cheaper. You won’t feel different. We’ll check your levels in 3 months.”
• Shared decision-making: You should have a say. If you’re anxious, ask for a delay. If you’re okay, sign the consent form.
• Monitoring: Blood tests for drug levels and antibodies. Disease activity scores. Follow-ups at 4, 12, and 24 weeks.
• Support: Some clinics use apps or pamphlets to walk patients through what to expect. One study cut discontinuation from 18% to just 6.4% with this approach.

Pharmacists in Europe can automatically substitute biosimilars - no doctor input needed. In the U.S., that’s only allowed if the drug is designated “interchangeable.” The first interchangeable adalimumab biosimilar, Cyltezo, got FDA approval in 2024. That means in states that allow substitution, you might get a biosimilar at the pharmacy without even knowing.

The Big Picture: Cost vs. Control

Biosimilars have saved healthcare systems billions. In Europe, 67% of filgrastim prescriptions are biosimilars. In the U.S., it’s only 24% for infliximab - partly because drugmakers use rebates and patent tricks to block competition. But that’s changing. By 2023, 85% of U.S. health plans had mandatory switch policies.

For patients, that means lower out-of-pocket costs. For the system, it means more people can get treatment. But it also means less control. If you’re forced to switch without input, trust drops. And trust is everything in chronic disease management.

What’s Next?

The NOR-SWITCH II study, tracking patients for two years after multiple switches, found 89.2% were still on treatment. That’s strong evidence that even repeated switches are safe.

Regulators are catching up. The FDA now requires switching studies for interchangeability. The EMA says switching is fine - no extra proof needed. Canada still warns that biologics are too complex to copy exactly. But the data is clear: for the vast majority, biosimilar switching works.

The real challenge isn’t science. It’s communication. If you’re switched without explanation, you’ll feel like a lab rat. If you’re switched with clarity, support, and time - you’ll barely notice the change.